This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

A 3-Year Naturalistic Study of 53 Preschool Children With Pervasive Developmental Disorders Treated With Risperidone

Gabriele Masi, MD; Angela Cosenza, MD; Maria Mucci, MD; and Paola Brovedani, PhD

Published: September 15, 2003

Article Abstract

Background: Only sparse and short-term data are available on pharmacologic treatments in very young children with pervasive developmental disorders (PDD). The purpose of this 3-year naturalistic study (March 1999-April 2002) is to describe the clinical outcome of a consecutive sample of preschool children with PDD treated with risperidone monotherapy.

Method: The sample consisted of 45 boys and 8 girls aged 3.6 to 6.6 years (mean ± SD age = 4.6 ± 0.7 years) with a DSM-IV diagnosis of autistic disorder or PDD, not otherwise specified. Outcome measures included the Children’s Psychiatric Rating Scale (CPRS), Clinical Global Impressions-Improvement scale (CGI-I), Children’s Global Assessment Scale (CGAS), and a checklist for risperidone side effects.

Results: Patients received risperidone for a period ranging from 1 to 32 months (7.9 ± 6.8 months). Twenty-five patients (47.2%) continued to receive risperidone after the study was completed, while 28 (52.8%) discontinued due to side effects (22.6% [N = 12]), parents’ choice (18.9% [N = 10]), lack of efficacy (5.7% [N = 3]), and decision of the treating psychiatrist (5.7% [N = 3]). The optimal dose was 0.55 ± 0.2 mg/day. Significant improvement at the last observation was found in CPRS (p < .0001) and CGAS (p < .0001) scores. On the basis of both an improvement of 25% in CPRS score and a score of 1 or 2 on the CGI-I, 46.8% (N = 22) of subjects were considered responders. Behavioral disorders and affect dysregulation were more sensitive to treatment than was interpersonal functioning. Responders received higher doses of medication for a longer period and had a greater weight gain than did nonresponders. Increased prolactin levels without clinical signs (65% [24 of 37]) and increased appetite (15% [8 of 53]) were the most frequent side effects.

Conclusion: These findings suggest that low-dose risperidone may positively affect the clinical outcome in young children with PDD not only in the short-term, but also in the long-term period.

Volume: 64

Quick Links: Child and Adolescent , Populations

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF